Global

SHERIDAN, WYOMING - December 2, 2025 - Ricoh and Neat have signed a global partnership agreement to deliver integrated, high-end audiovisual solutions for modern workplaces worldwide, combining Neat's AI-driven video devices with Ricoh's AV Managed Services to enhance hybrid collaboration and workplace experience.

Master-level alliance to scale premium meeting experiences

Under the agreement, Neat, a global leader in professional AV and innovative video technology, and Ricoh, a global leading AV integrator, will collaborate at the highest tier of Neat's Global Partner Program-the Mastery level. The partnership is designed to expand Ricoh's portfolio of high-end meeting room solutions and make Neat-powered spaces more accessible across enterprises of all sizes.

SHERIDAN, WYOMING - December 2, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) is restructuring its largest site in Wiesloch-Walldorf, appointing long-time manager Orhan Bekyigit as plant director alongside his existing role as site head, in a move designed to sharpen competitiveness, streamline operations and support growth in international markets.

Strategic realignment at Heidelberg's largest production hub

The Wiesloch-Walldorf campus, with around 3,800 employees, is HEIDELBERG's biggest location worldwide and a central pillar of its global manufacturing and technology network. The new setup brings plant management and central site functions under one leadership, with Bekyigit now responsible for both operational execution and cross-site coordination.

SHERIDAN, WYOMING - December 2, 2025 - More than 3,000 print service providers worldwide are now using the cloud-based HEIDELBERG Customer Portal as a digital control center for their end-to-end production, underscoring how system integration and workflow automation are becoming decisive competitive factors in the global print and packaging industry.

Cloud platform becomes a digital command center for print plants

Three years after launch, Heidelberger Druckmaschinen AG's (HEIDELBERG) customer portal is evolving into a central hub for managing production, service and commercial processes. Over 7,000 individual users are actively leveraging the platform to digitalize and automate their operations, with a clear focus on improving efficiency, transparency and sustainability.

SHERIDAN, WYOMING - December 2, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) is reporting a significantly more profitable first half of its 2025/2026 financial year, with revenue growth, a doubling of EBITDA and improving cash flow underscoring the impact of its restructuring program and strategic focus on packaging, label and digital print.

Stronger top line and sharply improved margins

In the six months from April 1 to September 30, 2025, HEIDELBERG grew revenue to €985 million, around 8% above the prior-year period's €915 million. Europe and Asia were the main regional growth engines, while the second quarter contributed €519 million, up from €466 million in the first quarter despite negative currency effects of roughly €12 million versus the prior-year quarter.

SHERIDAN, WYOMING - December 2, 2025 - Roche has reported landmark Phase III results for its oral selective estrogen receptor degrader (SERD) giredestrant, positioning the candidate as a potential new standard of care in early-stage ER-positive, HER2-negative breast cancer after a pivotal trial showed superior invasive disease-free survival versus standard endocrine therapy.

First oral SERD to show superior invasive disease-free survival

The Phase III lidERA Breast Cancer study evaluated adjuvant giredestrant against standard-of-care endocrine monotherapy in more than 4,100 patients with medium- or high-risk stage I-III ER-positive, HER2-negative early breast cancer. At a pre-planned interim analysis, the trial met its primary endpoint: giredestrant delivered a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy.

SHERIDAN, WYOMING - December 2, 2025 - Royal Philips is expanding commercial availability of its LumiGuide 3D Device Guidance solution across Europe and the United States, positioning its real-time, AI-enabled, light-based navigation technology as a new benchmark for radiation-free image-guided therapy in complex endovascular procedures.

Real-time 3D navigation without continuous X-ray

SHERIDAN, WYOMING - December 2, 2025 - Roche is re-entering the frontline of Alzheimer's disease drug development, after new Phase I/II data showed its next-generation antibody trontinemab cleared amyloid plaques below the threshold of positivity in the vast majority of treated patients while keeping key safety signals under tight control.

Early Brainshuttle data show deep amyloid clearance

In the ongoing Brainshuttle AD Phase I/II study, 92% of patients treated with trontinemab achieved amyloid levels below 24 centiloids, the PET scan threshold commonly used to define amyloid positivity. The data, presented at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, mark one of the strongest plaque-clearing signals yet seen in a mid-stage program.

SHERIDAN, WYOMING - December 2, 2025 - A leaked memo from FDA vaccine chief Vinay Prasad alleging that COVID-19 vaccines caused the deaths of 10 children has triggered a sharp backlash from scientific experts and investors, underscoring deep tensions inside U.S. vaccine regulation and adding fresh volatility for mRNA players Moderna and BioNTech.

An internal memo with external market consequences

In a six-page document titled "Deaths in children due to COVID-19 vaccines and CBER's path forward," Center for Biologics Evaluation and Research head Vinay Prasad claimed that an internal investigation had identified 10 child deaths "linked" to COVID-19 vaccination, based on reports in the Vaccine Adverse Events Reporting System (VAERS). The memo, published by The Washington Post, did not provide specific data, case details or manufacturer names.

SHERIDAN, WYOMING - December 2, 2025 - Imvax is moving its autologous glioblastoma immunotherapy IGV-001 toward the FDA, despite a missed primary endpoint in Phase IIb, betting that a six-month overall survival benefit and a novel "synergistic" treatment concept will resonate in a setting where outcomes have barely budged in two decades.

Phase IIb data highlight survival benefit despite PFS miss

In a mid-stage trial of 99 patients with newly diagnosed glioblastoma, Imvax evaluated IGV-001, a biologic-device combination, against placebo. While the study did not achieve its primary endpoint of improving progression-free survival, the company reported a median overall survival of 20.3 months in the treatment arm-around six months longer than in the control group.

SHERIDAN, WYOMING - December 2, 2025 - After years of volatility in Alzheimer's R&D, Roche's re-emergence with positive early data for trontinemab is reshaping expectations for the next competitive cycle in disease-modifying therapies, signaling that big pharma is not done pushing for better outcomes in this high-risk, high-need market.

From Aduhelm's fallout to a more mature Alzheimer's market

The modern Alzheimer's era was defined-some would say scarred-by the 2021 approval of Biogen and Eisai's Aduhelm, a controversial and costly monoclonal antibody that ultimately failed to deliver convincing clinical benefit and was later withdrawn. The backlash damaged Biogen's reputation and, for a time, cast doubt on the entire amyloid-directed approach, raising questions about regulatory standards and payer willingness to back expensive, marginally effective therapies.